Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees.  Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).

Eli Lilly & Co. terlibat dalam penemuan, pengembangan, pembuatan, dan penjualan produk farmasi. Perusahaan ini berkantor pusat di Indianapolis, Indiana dan saat ini mempekerjakan 47.000 karyawan penuh waktu. Produk kesehatan kardiometaboliknya meliputi Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, dan lainnya; Humulin, Humulin 70/30, dan lainnya; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, dan VERVE-301. Produk onkologi-nya termasuk Cyramza, Erbitux, Tyvyt, dan Verzenio. Produk imunologinya meliputi Ebglyss, Olumiant, Omvoh, dan Taltz. Produk neuro ilmiah-nya termasuk Emgality dan Kisunla. Perusahaan ini, melalui anak perusahaannya, POINT Biopharma Global Inc., terlibat dalam penemuan, pengembangan, dan upaya pembuatan radiopharmaceutical, serta terapi radioligand klinis dan pra-klinis yang sedang dikembangkan untuk pengobatan kanker. Perusahaan ini juga sedang mengembangkan penghambat molekul kecil oral a4b7 integrin untuk penyakit radang usus (IBD).

Eli Lilly

NVIDIA

Apple

Google

Microsoft

Amazon

Broadcom

Meta Platforms

Taiwan Semiconductor

Tesla

Berkshire Hathaway

Walmart

JPMorgan

Visa

Oracle

Johnson & Johnson

MasterCard

Exxon Mobil

Netflix

ASML

SPDR S&P500 ETF

Costco

AbbVie

Palantir

Bank of America

Alibaba

Home Depot

Procter & Gamble

UnitedHealth Group

Cisco

General Electric

Vanguard Total Stock Market ETF

Coca-Cola

Chevron

AstraZeneca

Morgan Stanley

Wells Fargo

Caterpillar

Micron Technology

Toyota

Novartis

Goldman Sachs

Merck

American Express

Philip Morris

T-Mobile

Raytheon Technologies

Salesforce

Abbott

McDonald's

Royal Bank of Canada

Shell

Applied Materials

Novo Nordisk

Intel

Shopify

Intuitive Surgical

PepsiCo

Invesco QQQ Trust

Lam Research

Linde PLC

Citigroup

Disney

QUALCOMM

Uber

Amgen

AT&T

Blackstone

Intuit

NextEra Energy

ServiceNow

Verizon

Sony

Accenture

Charles Schwab

Booking Holdings

Danaher

Banco Santander

BlackRock

Arista Networks

Texas Instruments

Boeing

Gilead Sciences

S&P Global

Unilever

Boston Scientific

Toronto-Dominion Bank

Capital One

Pfizer

TotalEnergies

Adobe

Union Pacific

Lowe's

Palo Alto Networks

Saham Eli Lilly

Tentang Eli Lilly

Statistik Kunci